• Judith Domínguez, Oscar Arrieta, Miguel A Celis, Sergio Islas, Alberto Lifshitz, Armando Mansilla, Iris Martínez, Alberto Mimenza, Mucio Moreno, Alejandro Reyes-Sánchez, Luisa Rocha, Guillermo Ruiz-Argüelles, Antonio Soda, Sonia Toussaint, Emma Verástegui, Diana Vilar-Compte, and Julio Sotelo.
• Academia Nacional de Medicina, Comité de Ética y Transparencia en la Relación Médico-Industria (CETREMI), Mexico City, Mexico.
• Gac Med Mex. 2022 Jan 1; 158 (3): 157-159.

AbstractDue to sanitary restrictions secondary to the COVID-19 pandemic, various interactions between the pharmaceutical industry and physicians have changed. One of them has been the method for promoting medicinal products through academic meetings around diseases of financial interest. A recent modality has been unilateral promotion by the pharmaceutical industry through academic events with the invitation of so-called "experts" for the promotion of a specific drug. These meetings are often biased not towards optimal care of a disease, but rather towards commercial promotion of a specific drug, which may or may not be the best option, without considering associated therapeutic alternatives. The Committee of Ethics and Transparency in the Physician-Industry Relationship, of the National Academy of Medicine, analyzes this new circumstance and proposes some considerations to the medical community.Copyright: © 2022 Permanyer.

10 keywords...

hide…